Prevalence and Correlates of Viral Load Suppression and Human Immunodeficiency Virus (HIV) Drug Resistance Among Children and Adolescents in South Rift Valley and Kisumu, Kenya
| Autor: | Isaac Tsikhutsu, Margaret Bii, Nicole Dear, Kavitha Ganesan, Alex Kasembeli, Valentine Sing’oei, Kevin Rombosia, Christopher Ochieng, Priyanka Desai, Vanessa Wolfman, Peter Coakley, Elizabeth H Lee, Patrick W Hickey, Jeffrey Livezey, Patricia Agaba |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Clin Infect Dis |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1093/cid/ciac059 |
| Popis: | Background Children and adolescents living with HIV (CALHIV) face unique challenges, including poorer treatment outcomes, risk for drug-resistance mutations (HIVDRMs), and limited drug formulations. We estimated viral suppression (VS) prevalence and evaluated predictors of VS and HIVDRMs in Kenya. Methods From 2018–2020, CALHIV 1–19 years on antiretroviral therapy (ART) >6 months were enrolled in this cross-sectional study. Participants underwent viral load (VL) testing; those with VL ≥1000 copies/mL had HIVDRM testing. Sociodemographic questionnaires and medical record abstraction were completed. VS prevalence (VL Results Nine hundred and sixty-nine participants were enrolled. VS prevalence was .80 (95% CI: .78–.83). Being on ART >24 months (adjusted PR [aPR]: 1.22; 95% CI: 1.06–1.41), an integrase strand transfer inhibitor–containing regimen (1.13; 1.02–1.26), and attending a level 3 health facility (1.23; 1.11–1.36) were associated with VS. Missing ≥3 doses of ART in the past month (aPR: .73; 95% CI: .58–.92), having a viremic mother with HIV (.72; .53–.98), and having 3–7 (.90; .83–.97), 8–13 (.89; .82–.97), or ≥14 (.84; .77–.92) compared with Conclusions HIV treatment programs should target interventions for pediatric patients at risk for treatment failure—namely, those with a caregiver with failed VS and those struggling with adherence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|